Intervention: Aprepitant
Trial phase: Phase 2
ATC code: A04AD12
SMILES: C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission

Fosaprepitant: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Eligibility criteria:
Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

Evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial.
Subjects who are willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Be at least 18 years of age at the time of informed consent.
Has a diagnosis of metastatic melanoma or metastatic renal cell carcinoma and who will undergo high-dose interleukin-2 (HD IL-2) therapy
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at Baseline/Day 1 visit. (See Appendix 6 on p. 51, ECOG Performance Status)
Female of reproductive potential must agree use non-hormonal methods to avoid pregnancy during study participation and for 1 month after last dose of study drug

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

Women who are pregnant or lactating, or planning pregnancy
Women of childbearing potential who refuse to use non-hormonal methods to avoid pregnancy
Known hypersensitivity to any component of fosaprepitant or aprepitant
Have taken pimozide or cisapride <4 weeks, cytochrome P450 3A4 inducers within 30 days, strong CYP3A4 inhibitors within 7 days, or antiemetics within 48 hours prior to treatment initiation (See Appendix 7 on p. 52 for list of CYP3A4 inducers and strong CYP3A4 inhibitors)
Have evidence of clinically significant and unstable diseases or conditions such as cardiovascular, immunosuppressive, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities that the investigator thinks may interfere with study participation
Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before study entry
Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Subjects who are investigational site staff members or who are Sponsor employees directly involved in the conduct of the trial.
A subject who, in the opinion of the investigator or sponsor, will be uncooperative or unable to comply with study procedures.